cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major CagriSema: a novel dual-pathway approach

Mucinex is a widely used over-the-counter medication designed to relieve chest congestion and help clear mucus from the lungs

Pro Tip: Before signing, ask your attorney to walk you through a hypothetical settlement calculation showing exactly how fees and expenses would be deducted

FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized

However, there are times when medical evaluation is warranted